Merck earns FDA approval for antiviral drug: 3 things to know

The Food and Drug Administration on Thursday approved Merck’s antiviral drug Prevymis to prevent cytomegalovirus infections in patients after a stem cell transplant, reports Reuters.

Advertisement

Here are three things to know.

1. The agency approved Prevymis as both a tablet, which will cost $195 per day, and as an infection, which will cost $270 per day.

2. The drug’s recommended dosing is once-daily for 100 days after the stem cell transplant.

3. Merck plans to launch Prevymis in December.

More articles on supply chain:

Sens. Chuck Grassley, Elizabeth Warren ask CMS to clarify position on unique device identifiers by Dec. 1
Indiana claims Nantworks failed to fulfill promises to state, seeks $1.4M
7 must-reads for supply chain leaders this week

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.